Form 4: HeartBeam CEO Robert Paul Eno Reports Stock Option Grant

HeartBeam, Inc. CEO Robert Paul Eno reports the acquisition of stock options.

Summary

• Robert Paul Eno, CEO of HeartBeam, Inc., filed a Form 4 on May 1, 2025, reporting a transaction.
• On April 7, 2025, Eno was granted 320,000 stock options with an exercise price of $1.65.
• The options vest over four years, with 25% vesting immediately on April 7, 2025, and the remainder vesting monthly thereafter.
• These options were issued under the company's 2022 Equity Incentive Plan.
• Following the reported transaction, Eno directly owns 856,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The option grant incentivizes the CEO, which is generally viewed favorably.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term performance.

Industry Context

Stock option grants are a common practice in the technology and biotech industries to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules, such as the four-year vesting with a one-year cliff, are also typical.
• The size of the grant would be benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the CEO successfully executes the company's strategy.
• Employees may be motivated by the alignment of executive incentives with company performance.

Key Dates

Keywords

stock options, Form 4, HeartBeam, CEO, Eno, Equity Incentive Plan, Vesting